GlaxoSmithKline's new strategy -- Viiv healthcare will be launched

Source: Biovalley, February 8, 2015, GSK, a pharmaceutical giant, released a series of performance growth plans after announcing its poor performance in the previous year, in order to make a good start in 2015 and regain the past in the second half of 2015 One of the plans is to sell part of its equity stake in Viiv healthcare, which CEO Andrew witty said: "we are confident that Viiv will be ranked in the top 50 of the Financial Times Index in London and easily in the top 30-40% of the financial times 100 index." In order to smooth the IPO, GSK even hired Citigroup, Morgan Stanley and Goldman Sachs investment as advisers Founded in 2009, Viiv healthcare focuses on HIV / AIDS GSK owns 80% of the equity of Viiv, and the rest is owned by Pfizer in the United States and ye Yanyi pharmaceutical company in Japan Viiv is one of the most outstanding subsidiaries of GSK group, with revenue growth of nearly 15% last year Its products are sold to 135 countries around the world and serve 26 million HIV patients It is estimated that tivicay, the star product of Viiv, will generate revenue of US $1.102 billion in 2015! There are more than a dozen other HIV drugs on the market and under research "Viiv is in a period of rapid development, and its business will expand more and more widely," said Andrew witty When the company was founded, professionals believed that the new company would be listed one day Indeed, in October 2014, GSK released a message that Viiv would go out on its own In this IPO, GSK will sell some of its shares, but will still own no less than 50%, witty said But whether Pfizer and ye Yanyi will sell their shares is unclear In the next two or three months, they will vote on the IPO, carefully evaluate the opinions of supporters and opponents, and decide how many shares to sell and which stock exchange to be superior to If Viiv goes public, GSK will earn $1.6 billion (up and down 20% float) GSK executives are expected to reach a final opinion on the Viiv IPO in mid-2015, after announcing the fiscal position for the second quarter of 2015 GSK also hopes that the IPO will regain the trust of investors and shareholders in GSK Despite the poor performance in the fourth quarter of 2014 and even the whole year, GSK is confident in the future, making a schedule of new initiatives and striving to bring back the situation before 2016 A GSK spokesman also firmly said: "this is a clear time limit."